-
1
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel, R., D. Naishadham, and A. Jemal . 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11-30.
-
(2013)
CA Cancer J. Clin.
, vol.63
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
84879079619
-
An international assessment of ovarian cancer incidence and mortality
-
Lowe, K. A.. et al., 2013. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol., 130:107-114.
-
(2013)
Gynecol. Oncol.
, vol.130
, pp. 107-114
-
-
Lowe, K.A.1
-
3
-
-
11844278537
-
Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000
-
Bray, F., et al. 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int. J. Cancer 113:977-990.
-
(2005)
Int. J. Cancer
, vol.113
, pp. 977-990
-
-
Bray, F.1
-
4
-
-
11844278537
-
Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000
-
Bray, F., et al., 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. 113:977-990.
-
(2005)
, vol.113
, pp. 977-990
-
-
Bray, F.1
-
5
-
-
77952315345
-
Development of a multimarker assay for early detection of ovarian cancer
-
Yurkovetsky, Z., et al. 2010. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28:2159-2166.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2159-2166
-
-
Yurkovetsky, Z.1
-
6
-
-
48249137385
-
Early detection of ovarian cancer
-
Das, P. M., and R. C., Jr. Bast . 2008. Early detection of ovarian cancer. Biomark. Med. 2:291-303.
-
(2008)
Biomark. Med.
, vol.2
, pp. 291-303
-
-
Das, P.M.1
Bast, R.C.2
-
7
-
-
0345256652
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance
-
Siddik, Z. H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
-
(2003)
Oncogene
, vol.22
, pp. 7265-7279
-
-
Siddik, Z.H.1
-
8
-
-
18244379333
-
Cellular processing of platinum anticancer drugs
-
Wang, D., and S. J. Lippard . 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4:307-320.
-
(2005)
Nat. Rev. Drug Discov.
, vol.4
, pp. 307-320
-
-
Wang, D.1
Lippard, S.J.2
-
9
-
-
84859771379
-
Molecular mechanisms of cisplatin resistance
-
Galluzzi, L., et al. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883.
-
(2012)
Oncogene
, vol.31
, pp. 1869-1883
-
-
Galluzzi, L.1
-
10
-
-
34249321653
-
Mechanisms of resistance to cisplatin and carboplatin
-
Stewart, D. J. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63:12-31.
-
(2007)
Crit. Rev. Oncol. Hematol.
, vol.63
, pp. 12-31
-
-
Stewart, D.J.1
-
11
-
-
85026145371
-
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
-
Bock, A. J., et al. 2010. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int. J. Gynecol. Cancer 20:1448-1455.
-
(2010)
Int. J. Gynecol. Cancer
, vol.20
, pp. 1448-1455
-
-
Bock, A.J.1
-
12
-
-
77955555369
-
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
-
Staff, A. C., et al. 2010. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol. 118:237-243.
-
(2010)
Gynecol. Oncol.
, vol.118
, pp. 237-243
-
-
Staff, A.C.1
-
13
-
-
84871573868
-
Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer
-
Khaled, Y. S., E. Elkord, and B. J. Ammori . 2012. Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer. Cancer Biomark. 11:183-190.
-
(2012)
Cancer Biomark.
, vol.11
, pp. 183-190
-
-
Khaled, Y.S.1
Elkord, E.2
Ammori, B.J.3
-
14
-
-
67650671369
-
Growth-differentiation factor-15 in heart failure
-
Kempf, T., and K. C. Wollert . 2009. Growth-differentiation factor-15 in heart failure. Heart Fail. Clin. 5:537-547.
-
(2009)
Heart Fail. Clin.
, vol.5
, pp. 537-547
-
-
Kempf, T.1
Wollert, K.C.2
-
15
-
-
11144353917
-
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
-
Koopmann, J., et al. 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10:2386-2392.
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 2386-2392
-
-
Koopmann, J.1
-
16
-
-
0032948894
-
MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation
-
Fairlie, W. D., et al. 1999. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J. Leukoc. Biol. 65:2-5.
-
(1999)
J. Leukoc. Biol.
, vol.65
, pp. 2-5
-
-
Fairlie, W.D.1
-
17
-
-
18744405699
-
Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury
-
Zimmers, T. A., et al. 2005. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23:543-548.
-
(2005)
Shock
, vol.23
, pp. 543-548
-
-
Zimmers, T.A.1
-
18
-
-
2442701601
-
Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation
-
Yang, H., et al. 2003. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2:1023-1029.
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 1023-1029
-
-
Yang, H.1
-
19
-
-
0034331055
-
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
-
Rebbeck, T. R. 2000. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 18(Suppl. 21):100s-103s.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 100s-103s
-
-
Rebbeck, T.R.1
-
20
-
-
84873413504
-
The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer
-
Wang, X., S. J. Baek, and T. E. Eling . 2013. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol. 85:597-606.
-
(2013)
Biochem. Pharmacol.
, vol.85
, pp. 597-606
-
-
Wang, X.1
Baek, S.J.2
Eling, T.E.3
-
21
-
-
77954604008
-
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer
-
Mimeault, M., and S. K. Batra . 2010. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell. Physiol. 224:626-635.
-
(2010)
J. Cell. Physiol.
, vol.224
, pp. 626-635
-
-
Mimeault, M.1
Batra, S.K.2
-
22
-
-
41849104687
-
Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells
-
Kim, K. K., et al. 2008. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704-712.
-
(2008)
Carcinogenesis
, vol.29
, pp. 704-712
-
-
Kim, K.K.1
-
23
-
-
84858175766
-
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma
-
Corre, J., et al. 2012. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 72:1395-1406.
-
(2012)
Cancer Res.
, vol.72
, pp. 1395-1406
-
-
Corre, J.1
-
24
-
-
0023111825
-
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues
-
Behrens, B. C., et al. 1987. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414-418.
-
(1987)
Cancer Res.
, vol.47
, pp. 414-418
-
-
Behrens, B.C.1
-
25
-
-
84873740471
-
The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells
-
Galavotti, S., et al. 2013. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32:699-712.
-
(2013)
Oncogene
, vol.32
, pp. 699-712
-
-
Galavotti, S.1
-
26
-
-
0021023416
-
Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis
-
Cramer, D. W., W. R., Welch . 1983. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl Cancer Inst. 71:717-721.
-
(1983)
J. Natl Cancer Inst.
, vol.71
, pp. 717-721
-
-
Cramer, D.W.1
Welch, W.R.2
-
27
-
-
28844483193
-
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo
-
Dai, Y., et al. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 280:40066-40073.
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 40066-40073
-
-
Dai, Y.1
-
28
-
-
79956226810
-
SULFs in human neoplasia: implication as progression and prognosis factors
-
Bret, C., et al. 2011. SULFs in human neoplasia: implication as progression and prognosis factors. J. Transl. Med. 9:72.
-
(2011)
J. Transl. Med.
, vol.9
, pp. 72
-
-
Bret, C.1
-
29
-
-
0035971181
-
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α: a new model for anti-estrogen resistance
-
Campbell, R. A., et al. 2001. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817-9824.
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 9817-9824
-
-
Campbell, R.A.1
-
30
-
-
0036196994
-
Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer
-
Meier, C. R., S. Schmitz, and H. Jick . 2002. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303-309.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 303-309
-
-
Meier, C.R.1
Schmitz, S.2
Jick, H.3
-
31
-
-
70350225568
-
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling
-
Zhao, L., et al. 2009. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 69:7696-7703.
-
(2009)
Cancer Res.
, vol.69
, pp. 7696-7703
-
-
Zhao, L.1
-
32
-
-
84963044732
-
Determinants of ovarian cancer risk. I. Reproductive experiences and family history
-
Cramer, D. W., G. B. Hutchison, W. R. Welch, R. E. Scully, and K. J. Ryan . 1983. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J. Natl Cancer Inst.. 71:711-716.
-
(1983)
J. Natl Cancer Inst.
, vol.71
, pp. 711-716
-
-
Cramer, D.W.1
Hutchison, G.B.2
Welch, W.R.3
Scully, R.E.4
Ryan, K.J.5
-
33
-
-
61849084730
-
p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms
-
Kelly, J. A., M. S. Lucia, J. R. Lambert . 2009. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett. 277:38-47.
-
(2009)
Cancer Lett.
, vol.277
, pp. 38-47
-
-
Kelly, J.A.1
Lucia, M.S.2
Lambert, J.R.3
-
34
-
-
0025900804
-
Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer
-
Negri, E., et al. 1991. Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int. J. Cancer 49:50-56.
-
(1991)
Int. J. Cancer
, vol.49
, pp. 50-56
-
-
Negri, E.1
-
35
-
-
84869221003
-
Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer
-
Wang, L., et al. 2012. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol. Cancer Ther. 11:2401-2409.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 2401-2409
-
-
Wang, L.1
-
36
-
-
67649424560
-
p21 in cancer: intricate networks and multiple activities
-
Abbas, T., and A. Dutta . 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9:400-414.
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 400-414
-
-
Abbas, T.1
Dutta, A.2
-
37
-
-
84877280543
-
Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance
-
Singh, M., et al. 2013. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer 13:233.
-
(2013)
BMC Cancer
, vol.13
, pp. 233
-
-
Singh, M.1
-
39
-
-
73849152723
-
Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein
-
Abedini, M. R., et al. 2010. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29:11-25.
-
(2010)
Oncogene
, vol.29
, pp. 11-25
-
-
Abedini, M.R.1
-
40
-
-
0043016358
-
Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells
-
Liu, T., et al. 2003. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63:5034-5040.
-
(2003)
Cancer Res.
, vol.63
, pp. 5034-5040
-
-
Liu, T.1
-
41
-
-
0042134847
-
Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system
-
Lee, D. H., et al. 2003. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648-4655.
-
(2003)
Cancer Res.
, vol.63
, pp. 4648-4655
-
-
Lee, D.H.1
-
42
-
-
33750736082
-
Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia
-
Baek, S. J., et al. 2006. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131:1553-1560.
-
(2006)
Gastroenterology
, vol.131
, pp. 1553-1560
-
-
Baek, S.J.1
-
43
-
-
33745957772
-
Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth
-
Martinez, J. M., et al. 2006. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J. Pharmacol. Exp. Ther. 318:899-906.
-
(2006)
J. Pharmacol. Exp. Ther.
, vol.318
, pp. 899-906
-
-
Martinez, J.M.1
-
44
-
-
41149150219
-
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
-
Chu, I. M., L. Hengst, and J. M. Slingerland . 2008. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8:253-267.
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 253-267
-
-
Chu, I.M.1
Hengst, L.2
Slingerland, J.M.3
-
45
-
-
80155151895
-
Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice
-
Garcia-Fernandez, R. A., et al. 2011. Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice. Lab. Invest. 91:1634-1642.
-
(2011)
Lab. Invest.
, vol.91
, pp. 1634-1642
-
-
Garcia-Fernandez, R.A.1
-
46
-
-
58049216794
-
p53 regulates hematopoietic stem cell quiescence
-
Liu, Y., et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4:37-48.
-
(2009)
Cell Stem Cell
, vol.4
, pp. 37-48
-
-
Liu, Y.1
-
47
-
-
84857504660
-
Cellular senescence and tumor suppressor gene p16
-
Rayess, H., M. B. Wang, and E. S. Srivatsan . 2012. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 130:1715-1725.
-
(2012)
Int. J. Cancer
, vol.130
, pp. 1715-1725
-
-
Rayess, H.1
Wang, M.B.2
Srivatsan, E.S.3
-
48
-
-
40349116235
-
Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor
-
Surowiak, P., et al. 2008. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol. Histopathol. 23:531-538.
-
(2008)
Histol. Histopathol.
, vol.23
, pp. 531-538
-
-
Surowiak, P.1
-
49
-
-
28544452713
-
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
-
Bonome, T., et al. 2005. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65:10602-10612.
-
(2005)
Cancer Res.
, vol.65
, pp. 10602-10612
-
-
Bonome, T.1
-
50
-
-
60749137451
-
Beyond chemotherapy: targeted therapies in ovarian cancer
-
Yap, T. A., C. P. Carden, and S. B. Kaye . 2009. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 9:167-181.
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 167-181
-
-
Yap, T.A.1
Carden, C.P.2
Kaye, S.B.3
|